BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

...premiums larger than 100%. The two smallest premiums, in Principia’s acquisition by Sanofi (Euronext:SAN; NASDAQ:SNY) and Dermira’s...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...raised $560.9 million in a follow-on offering through the sale of 5.2 million shares at $108.Dermira...
...develop therapies for chronic inflammatory diseases. The start-up was co-founded by a trio of former Dermira Inc....
...autoimmune and dermatology company, joins as SVP, product development. Eli Lilly and Co. (NYSE:LLY) acquired Dermira...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

...TPEx:6497; NASDAQ:ASLN) hired Kenneth Kobayashi as CMO. He was a senior medical director at the Dermira Inc....
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...in March. SutroVax Inc. hired Andrew Guggenhime as CFO and CBO. He was CFO of Dermira Inc....
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...year’s only other billion-plus-dollar M&A deal in the sector was the buyout of dermatology company Dermira Inc....
...Challenger” ; “Only Biopharma to Make Offer After Outreach” ). Both the Forty Seven and Dermira...
BioCentury | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

...it would acquire Dermira for about $1.1 billion in cash at a 117% premium to Dermira’s...
...Dermira’s stock continued to climb and the company continued to reach out to other suitors. Dermira...
...February, Dermira granted Almirall S.A. (Madrid:ALM) an option to exclusively sub-license lebrikizumab in Europe. After Dermira...
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

...Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline...
...premium to Dermira’s last 60-day volume-weighted average price. Investors might be expecting a rival bid. Dermira...
...valuation by 66% in a day (see “Dermira Plummets After Phase III Acne Failure” ). Dermira’s...
BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...Regeneron gained $15.40 to $341.79 on Friday. Another company with a potential Dupixent competitor, Dermira Inc....
...more convenient than that of Dupixent. Lebrikizumab prevents IL-13RA1/IL-4R heterodimer formation and downstream signaling (see "Dermira...
...ANB020) REGN3500, SAR440340 Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) AnaptysBio Inc. Regeneron Pharmaceuticals Inc. Sanofi Dermira Inc. Interleukin-33...
BioCentury | Oct 19, 2019
Clinical News

Dermira data could bolster bid as Dupixent alternative

...support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing. Dermira Inc....
...Severity Index (EASI), at week 16 vs. placebo in adults with moderate-to-severe atopic dermatitis (see “Dermira...
...every 4 weeks. Thursday’s presentation at the Fall Clinical Dermatology Conference in Las Vegas drove Dermira...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:CBMG) 3/22/19 $17.5 $324.9 $317.8 -2% Oragenics Inc. (NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc....
Items per page:
1 - 10 of 87
BioCentury | Mar 4, 2021
Deals

How Pandion’s triple-digit premium ranks among recent biotech takeouts: Data Byte

...premiums larger than 100%. The two smallest premiums, in Principia’s acquisition by Sanofi (Euronext:SAN; NASDAQ:SNY) and Dermira’s...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...raised $560.9 million in a follow-on offering through the sale of 5.2 million shares at $108.Dermira...
...develop therapies for chronic inflammatory diseases. The start-up was co-founded by a trio of former Dermira Inc....
...autoimmune and dermatology company, joins as SVP, product development. Eli Lilly and Co. (NYSE:LLY) acquired Dermira...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

...TPEx:6497; NASDAQ:ASLN) hired Kenneth Kobayashi as CMO. He was a senior medical director at the Dermira Inc....
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...in March. SutroVax Inc. hired Andrew Guggenhime as CFO and CBO. He was CFO of Dermira Inc....
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...year’s only other billion-plus-dollar M&A deal in the sector was the buyout of dermatology company Dermira Inc....
...Challenger” ; “Only Biopharma to Make Offer After Outreach” ). Both the Forty Seven and Dermira...
BioCentury | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

...it would acquire Dermira for about $1.1 billion in cash at a 117% premium to Dermira’s...
...Dermira’s stock continued to climb and the company continued to reach out to other suitors. Dermira...
...February, Dermira granted Almirall S.A. (Madrid:ALM) an option to exclusively sub-license lebrikizumab in Europe. After Dermira...
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

...Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline...
...premium to Dermira’s last 60-day volume-weighted average price. Investors might be expecting a rival bid. Dermira...
...valuation by 66% in a day (see “Dermira Plummets After Phase III Acne Failure” ). Dermira’s...
BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...Regeneron gained $15.40 to $341.79 on Friday. Another company with a potential Dupixent competitor, Dermira Inc....
...more convenient than that of Dupixent. Lebrikizumab prevents IL-13RA1/IL-4R heterodimer formation and downstream signaling (see "Dermira...
...ANB020) REGN3500, SAR440340 Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) AnaptysBio Inc. Regeneron Pharmaceuticals Inc. Sanofi Dermira Inc. Interleukin-33...
BioCentury | Oct 19, 2019
Clinical News

Dermira data could bolster bid as Dupixent alternative

...support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing. Dermira Inc....
...Severity Index (EASI), at week 16 vs. placebo in adults with moderate-to-severe atopic dermatitis (see “Dermira...
...every 4 weeks. Thursday’s presentation at the Fall Clinical Dermatology Conference in Las Vegas drove Dermira...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:CBMG) 3/22/19 $17.5 $324.9 $317.8 -2% Oragenics Inc. (NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc....
Items per page:
1 - 10 of 87